Antonia Lopez‐Girona

6.2k total citations · 2 hit papers
58 papers, 3.6k citations indexed

About

Antonia Lopez‐Girona is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Antonia Lopez‐Girona has authored 58 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 30 papers in Hematology and 15 papers in Oncology. Recurrent topics in Antonia Lopez‐Girona's work include Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (26 papers) and DNA Repair Mechanisms (14 papers). Antonia Lopez‐Girona is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (26 papers) and DNA Repair Mechanisms (14 papers). Antonia Lopez‐Girona collaborates with scholars based in United States, Spain and Switzerland. Antonia Lopez‐Girona's co-authors include Paul Russell, Beth Furnari, Odile Mondesert, Derek Mendy, Brian E. Cathers, Peter Schäfer, Laura G. Corral, Paul Shanahan, Michael N. Boddy and Emily Rychak and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Antonia Lopez‐Girona

57 papers receiving 3.5k citations

Hit Papers

Cereblon is a direct protein target for immunomodulatory ... 2012 2026 2016 2021 2012 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
    2012 606 citations Antonia Lopez‐Girona, Derek Mendy et al. profile →
  2. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
    2014 371 citations Antonia Lopez‐Girona, Karen Miller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antonia Lopez‐Girona United States 22 3.1k 1.2k 1.1k 587 270 58 3.6k
Nicholas Kwiatkowski United States 31 3.2k 1.0× 393 0.3× 1.5k 1.4× 478 0.8× 118 0.4× 48 3.9k
Péter Sandy United States 17 3.0k 1.0× 629 0.5× 994 0.9× 203 0.3× 258 1.0× 27 3.5k
Daniel Afar United States 33 2.0k 0.6× 1.5k 1.2× 1.1k 1.0× 266 0.5× 835 3.1× 68 4.0k
Gary W. Reuther United States 24 1.5k 0.5× 579 0.5× 538 0.5× 292 0.5× 220 0.8× 49 2.3k
Dennis L. Buckley United States 22 5.8k 1.9× 1.4k 1.1× 1.7k 1.6× 199 0.3× 211 0.8× 35 6.2k
Madhavi Bandi United States 11 1.2k 0.4× 485 0.4× 734 0.7× 744 1.3× 236 0.9× 20 1.9k
Danette L. Daniels United States 29 3.7k 1.2× 523 0.4× 788 0.7× 283 0.5× 206 0.8× 46 4.1k
Yosef Landesman United States 33 2.5k 0.8× 640 0.5× 935 0.9× 112 0.2× 232 0.9× 171 3.2k
Cassandra J. Vandenberg Australia 19 2.2k 0.7× 301 0.2× 912 0.8× 165 0.3× 553 2.0× 44 2.9k
Rekha Rao United States 25 1.8k 0.6× 506 0.4× 401 0.4× 238 0.4× 170 0.6× 49 2.2k

Countries citing papers authored by Antonia Lopez‐Girona

Since Specialization
Citations

This map shows the geographic impact of Antonia Lopez‐Girona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonia Lopez‐Girona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonia Lopez‐Girona more than expected).

Fields of papers citing papers by Antonia Lopez‐Girona

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonia Lopez‐Girona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonia Lopez‐Girona. The network helps show where Antonia Lopez‐Girona may publish in the future.

Co-authorship network of co-authors of Antonia Lopez‐Girona

This figure shows the co-authorship network connecting the top 25 collaborators of Antonia Lopez‐Girona. A scholar is included among the top collaborators of Antonia Lopez‐Girona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonia Lopez‐Girona. Antonia Lopez‐Girona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carrancio, Soraya, Lynda Groocock, Ryan Galasso, et al.. (2021). CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma. Blood. 138(Supplement 1). 1200–1200. 12 indexed citations
2.
Lopez‐Girona, Antonia, Lynda Groocock, Zhongying Mo, et al.. (2021). CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 39(S2). 4 indexed citations
3.
Lopez‐Girona, Antonia, Gang Lu, Emily Rychak, et al.. (2019). CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 2703–2703. 16 indexed citations
4.
Narla, Rama Krishna, Hardik Modi, Lilly Wong, et al.. (2017). Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Research. 77(13_Supplement). 4694–4694. 13 indexed citations
5.
Ren, Yan, Maria Wang, Suzana S. Couto, et al.. (2015). A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. Applied immunohistochemistry & molecular morphology. 24(10). 695–702. 13 indexed citations
6.
Chen, Xi, Elena Díaz‐Rodríguez, Enrique M. Ocio, et al.. (2014). Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. Molecular Cancer Therapeutics. 13(2). 504–516. 8 indexed citations
7.
8.
Thakurta, Anjan, Anita K. Gandhi, Michelle F. Waldman, et al.. (2013). Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance. Blood. 122(21). 3139–3139. 3 indexed citations
9.
Gandhi, Anita K., Derek Mendy, Michelle F. Waldman, et al.. (2013). Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. British Journal of Haematology. 164(2). 233–244. 71 indexed citations
10.
Lopez‐Girona, Antonia, Daniel Heintel, Derek Mendy, et al.. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. British Journal of Haematology. 154(3). 325–336. 137 indexed citations
11.
Gandhi, Anita K., Lori Capone, Anastasia Parton, et al.. (2010). Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function. Current Cancer Drug Targets. 10(2). 155–167. 142 indexed citations
12.
Gaidarova, Svetlana, Gordafaried Deyanat‐Yazdi, Brydon L. Bennett, & Antonia Lopez‐Girona. (2009). Abstract #5236: Lenalidomide affects F-Actin cytoskeleton in mantle cell lymphoma cells in vitro. Cancer Research. 69. 5236–5236. 1 indexed citations
13.
Gaidarova, Svetlana, Laura G. Corral, Emilia Glezer, Peter Schäfer, & Antonia Lopez‐Girona. (2009). Treatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing.. Blood. 114(22). 1687–1687. 6 indexed citations
14.
15.
16.
Boddy, Michael N., Paul Shanahan, W. Hayes McDonald, et al.. (2003). Replication Checkpoint Kinase Cds1 Regulates Recombinational Repair Protein Rad60. Molecular and Cellular Biology. 23(16). 5939–5946. 76 indexed citations
17.
Lopez‐Girona, Antonia, Junko Kanoh, & Paul Russell. (2001). Nuclear exclusion of Cdc25 is not required for the DNA damage checkpoint in fission yeast. Current Biology. 11(1). 50–54. 58 indexed citations
18.
Rhind, Nick, Antonia Lopez‐Girona, Michael N. Boddy, et al.. (2000). DNA Damage Checkpoint Control of Mitosis in Fission Yeast. Cold Spring Harbor Symposia on Quantitative Biology. 65(0). 353–360. 2 indexed citations
19.
Lopez‐Girona, Antonia, Marta Bosch, Oriol Bachs, & Neus Agell. (1995). Addition of calmodulin antagonists to NRK cells during G1 inhibits proliferating cell nuclear antigen expression. Cell Calcium. 18(1). 30–40. 13 indexed citations
20.
Agell, Neus, María Jesús Pujol, Antonia Lopez‐Girona, et al.. (1994). Calmodulin Expression During Rat Liver Regeneration. Hepatology. 20(4). 1002–1008. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas Kwiatkowski Breakdown of academic impact, for papers by Péter Sandy Breakdown of academic impact, for papers by Daniel Afar Breakdown of academic impact, for papers by Gary W. Reuther Breakdown of academic impact, for papers by Dennis L. Buckley Breakdown of academic impact, for papers by Madhavi Bandi Breakdown of academic impact, for papers by Danette L. Daniels Breakdown of academic impact, for papers by Yosef Landesman Breakdown of academic impact, for papers by Cassandra J. Vandenberg Breakdown of academic impact, for papers by Rekha Rao
Rankless by CCL
2026